Abstract 5035
Background
Although pancreatic cancer has irregular shape in three-dimensional (3D), when T staging by imaging, only the axial plane is generally used to measure the largest diameter of the mass. We analysed the size of the pancreatic cancer from multi-plane and 3D reconstructed CT images and investigated their clinical usefulness.
Methods
Patients who underwent surgery for pancreatic adenocarcinoma from 2009 to 2016 were included in this study. We measured the largest diameter of pancreatic cancer in axial, coronal, and sagittal planes of CT. In addition, semi-automated segmentation was performed and three-dimensional (3D) maximal diameter and cancer volume were obtained. The obtained data were compared with the actual pathology report and the effect of each value on prognosis was analyzed by receiver operating characteristics (ROC) curves.
Results
A total of 183 patients were analyzed. The maximal pathologic diameter of cancer was 3.4 ± 1.4 cm and median survival was 18.1 months. The maximal diameters measured in axial, coronal, and sagittal planes were 2.9 ± 1.1, 3.2 ± 1.0, and 3.2 ± 0.9, respectively, which were significantly smaller than pathologic data (all p < 0.05 by paired T test). The longest diameter among measured on the 3 planes (3.4 ± 1.1) were not significantly different from that of pathologic report and maximal diameter from 3D image (3.8 ± 1.3) was larger than pathologic diameter. Cancer volume demonstrated the higher area under the ROC curve [0.714, (95% confidence interval: 0.640-0.788)] in predicting early death within 18 months than any measured diameter.
Conclusions
The diameter of pancreatic cancer needs to be measured on all of axial, coronal, and sagittal planes of CT. Cancer volume had a stronger correlation with overall survival than cancer diameter.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The National Research Foundation of Korea.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
870 - Selective Wnt/β-catenin small-molecule inhibitor CWP232228 impairs tumor growth of colon cancer
Presenter: Jin Young Kim
Session: Poster Display session 2
Resources:
Abstract
3425 - Feasibility and impact of prospective DPYD screening in the Irish population
Presenter: Mohammed Zameer
Session: Poster Display session 2
Resources:
Abstract
1972 - Diet-derived metabolites and the risk of colorectal cancer: a nested case-control study in a population-based cohort, the Singapore Chinese Health Study
Presenter: Dawn Chong
Session: Poster Display session 2
Resources:
Abstract
4103 - Loss of subcutaneous adipose tissue during chemotherapy predicts reduced survival in patients with incurable colorectal cancer undergoing palliative therapy
Presenter: Erin Stella Sullivan
Session: Poster Display session 2
Resources:
Abstract
4309 - Obese and overweight is associated with better prognosis in metastatic colorectal cancer patients treated with bevacizumab.
Presenter: Bozena Cybulska-Stopa
Session: Poster Display session 2
Resources:
Abstract
3554 - Patient characteristics associated with poor performance status, ECOG 2-3, and effect on survival in 1086 Finnish metastatic colorectal cancers (mCRC) nationwide (prospective RAXO study)
Presenter: Pia Österlund
Session: Poster Display session 2
Resources:
Abstract
4572 - Discovery and Diagnosis of Metastatic Colorectal Cancer (mCRC) in the Real World: Final Results from a European Survey
Presenter: Iga Rawicka
Session: Poster Display session 2
Resources:
Abstract
4783 - Adherence to recommended intake of calcium and colorectal cancer risk in the HEXA study
Presenter: Jeeyoo Lee
Session: Poster Display session 2
Resources:
Abstract
5106 - Body size, sex and sidedness of incident colorectal cancer in a prospective Swedish cohort study
Presenter: Christina Siesing
Session: Poster Display session 2
Resources:
Abstract
3364 - Middle East & North Africa Registry to characterize RAS mutation status and tumor specifications in recently diagnosed patients with metastatic colorectal cancer (MORE-RAS Study)
Presenter: Mohamed Oukkal
Session: Poster Display session 2
Resources:
Abstract